Abstract
There is evidence that P-glycoprotein (P-gp) in the blood–brain barrier (BBB) may be involved in the aetiology of neurological disorders. For quantification of P-gp function in vivo, ( R)-[ 11C]verapamil can be used as a positron emission tomography (PET) tracer, provided that a mathematical model describing kinetics of uptake and clearance of verapamil is available. To develop and validate such a model, the kinetic profile and metabolism of ( R)-[ 11C]verapamil have to be known. The aim of this study was to investigate the presence of labeled metabolites of [ 11C]verapamil in the plasma and (brain) tissue of Wistar rats. For this purpose, extraction and high-performance liquid chromatography (HPLC) methods were developed. The radioactive metabolites of ( R)-[ 11C]verapamil in the liver were N-dealkylated compounds, O-demethylated compounds and a polar fraction formed from N-demethylation products of ( R)-[ 11C]verapamil. Apart from this [ 11C] polar fraction, other radioactive metabolites of [ 11C]verapamil were not detected in the brain tissue. Thirty minutes after injection, unmetabolized ( R)-[ 11C]verapamil accounted for 47% of radioactivity in the plasma and 69% in the brain. Sixty minutes after injection, unmetabolized ( R)-[ 11C] verapamil was 27% and 48% in the plasma and the brain, respectively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
